ABSTRACT
<p><b>BACKGROUND</b>Hyaluronan (HA) is most likely associated with tumor invasion and metastasis. Studies have shown that HA levels are often increased in serum of patients with various malignant tumors. The purpose of this study was to determine the levels of serum hyaluronan in patients with oral cancer and evaluate the value of serum HA in adjuvant diagnosis, staging and monitoring treatment response in these patients.</p><p><b>METHODS</b>Eighty-four hospitalized patients with oral cancer, 65 patients with benign tumors in the oral and maxillofacial region and 67 healthy individuals were included in this investigation. Venous blood was collected from these patients and the healthy individuals before therapy. One week after therapy, venous blood was collected once again in 43 patients with oral cancer. Serum samples were obtained and serum HA levels examined.</p><p><b>RESULTS</b>The serum HA concentration was significantly higher in oral cancer patients than in patients with benign tumors and in healthy controls (P<0.05). The serum HA level in patients with stages III and IV disease was higher than in patients with stages I and II disease, but there was no significant difference in the HA level between stages I and II nor between stages III and IV (P>0.05). After a complete treatment the HA levels in patients with oral cancer became lower than before treatment, but the difference was not significant (P>0.05).</p><p><b>CONCLUSIONS</b>The results of this study suggest that the determination of HA levels may provide additional information in diagnosis of oral cancer, but its usefulness as an adjunct in clinical staging and in monitoring treatment response was limited.</p>
Subject(s)
Aged , Humans , Middle Aged , Hyaluronic Acid , Blood , Mouth Neoplasms , Blood , Pathology , Therapeutics , Neoplasm StagingABSTRACT
<p><b>OBJECTIVE</b>To determine the level of hyaluronic acid (HA) in serum of patients with oral and maxillofacial malignancy and to investigate the correlation between the levels of serum HA and stage of the malignant lesions and treatment response.</p><p><b>METHODS</b>44 patients with oral and maxillofacial malignancy were analyzed and 24 healthy individuals served as controls. Venous blood was collected from the patients before treatment and the healthy individuals. One week after therapy, venous blood were collected in 24 patients once again. Serum levels of HA were measured with quantitative radioimmunoassay (RIA).</p><p><b>RESULTS</b>Before treatment, the serum HA concentration in patients with oral and maxillofacial malignancy was significantly higher than that of the controls (P < 0.05). Also, the serum HA concentration in patients with OSCC was significantly higher than that of the controls (P < 0.05). No difference was noted in serum HA concentration between patients with salivary ACC and the control group (P > 0.05). The serum HA concentration of patients in stage III and IV was significantly higher than that of patients in stage I and II (P < 0.05). Serum HA levels decreased in patients after a complete treatment, but the difference was not significant (P > 0.05).</p><p><b>CONCLUSION</b>Serum levels of HA may be useful in diagnosis of OSCC and was associated with clinical stages in patients with oral and maxillofacial malignancy. However, it may not be contributory to monitoring treatment response in patients with oral and maxillofacial malignancy.</p>